Olaparib, a PARPi, is being evaluated in adjuvant setting in a randomized phase II trial for resectable pancreatic cancer with germline BRCA1/2 or PALB2 mutation after perioperative chemotherapy (NCT04858334). Here, PALB2 is linked to pancreatic neoplasm.